LAUR Repository

Show simple item record

dc.contributor.author Mansour, Hanine
dc.contributor.author Chahine, Elias B.
dc.contributor.author Karaoui, Lamis R.
dc.contributor.author El-Lababidi, Rania M.
dc.date.accessioned 2016-09-29T13:12:42Z
dc.date.available 2016-09-29T13:12:42Z
dc.date.copyright 2013 en_US
dc.identifier.issn 1060-0280 en_US
dc.identifier.uri http://hdl.handle.net/10725/4458
dc.description.abstract OBJECTIVE To review the pharmacology, chemistry, microbiology, in vitro susceptibility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new ketolide antibiotic. DATA SOURCES Literature was obtained through searching PubMed (1950-October 2012), International Pharmaceutical Abstracts (1970-October 2012), and a bibliographic review of published articles. Search terms included cethromycin, ABT-773, ketolide antibiotic, and community-acquired pneumonia. STUDY SELECTION AND DATA EXTRACTION All available in vitro and preclinical studies, as well as Phase 1, 2, and 3 clinical studies published in English were evaluated to summarize the pharmacology, chemistry, microbiology, efficacy, and safety of cethromycin in the treatment of respiratory tract infections. DATA SYNTHESIS Cethromycin, a new ketolide, has a similar mechanism of action to telithromycin with an apparently better safety profile. Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. The proposed indication of cethromycin is treatment of mild to moderate community-acquired bacterial pneumonia in patients aged 18 years or older. Based on clinical studies, the recommended dose is 300 mg orally once a day without regard to meals. Cethromycin has an orphan drug designation for tularemia, plague, and anthrax prophylaxis. The Food and Drug Administration denied approval for the treatment of community-acquired pneumonia in 2009; a recent noninferiority trial showed comparable efficacy between cethromycin and clarithromycin. Preliminary data on adverse effects suggest that cethromycin is safe and gastrointestinal adverse effects appear to be dose-related. CONCLUSIONS Cethromycin appears to be a promising ketolide for the treatment of mild to moderate community-acquired pneumonia. It was denied approval by the FDA in 2009 pending more evidence to show its efficacy, with more recent studies showing its noninferiority to antibiotics for the same indication. en_US
dc.language.iso en en_US
dc.title Cethromycin en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle A New Ketolide Antibiotic en_US
dc.author.school SOP en_US
dc.author.idnumber 201205628 en_US
dc.author.idnumber 200101817 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal Annals of Pharmacotherapy en_US
dc.journal.volume 47 en_US
dc.journal.issue 3 en_US
dc.article.pages 368-379 en_US
dc.identifier.doi http://dx.doi.org/10.1345/aph.1R435 en_US
dc.identifier.ctation Mansour, H., Chahine, E. B., Karaoui, L. R., & El-Lababidi, R. M. (2013). Cethromycin: a new ketolide antibiotic. Annals of Pharmacotherapy, 47(3), 368-379. en_US
dc.author.email hanine.mansour@lau.edu.lb en_US
dc.author.email lamis.karaoui@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://aop.sagepub.com/content/47/3/368.short en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account